Tonix Pharmaceuticals uplists from Nasdaq Capital Market to Global Select Market

Tonix Pharmaceuticals Holding Corp.

Nasdaq approved transfer of TNXP common stock, effective March 3, 2026, ticker unchanged.
Uplisting reflects compliance with higher financial and corporate governance standards.
CEO Seth Lederman noted uplisting may enhance visibility, liquidity, and institutional access.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.